7.345
price up icon2.04%   0.155
 
loading
前日終値:
$7.19
開ける:
$7.235
24時間の取引高:
2.90M
Relative Volume:
1.12
時価総額:
$530.44M
収益:
$409.00K
当期純損益:
$-101.35M
株価収益率:
-4.4787
EPS:
-1.64
ネットキャッシュフロー:
$-71.49M
1週間 パフォーマンス:
+8.21%
1か月 パフォーマンス:
+28.49%
6か月 パフォーマンス:
-2.82%
1年 パフォーマンス:
-0.99%
1日の値動き範囲:
Value
$6.89
$7.375
1週間の範囲:
Value
$6.635
$7.52
52週間の値動き範囲:
Value
$3.553
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
名前
Altimmune Inc
Name
セクター
Healthcare (1172)
Name
電話
(240) 654-1450
Name
住所
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
職員
59
Name
Twitter
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
ALT's Discussions on Twitter

ALT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ALT
Altimmune Inc
7.345 530.44M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.88 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.97 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.08 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
563.58 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.35 28.51B 3.81B -644.79M -669.77M -6.24

Altimmune Inc Stock (ALT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-02-28 開始されました William Blair Mkt Perform
2025-01-08 開始されました Stifel Buy
2024-11-12 開始されました UBS Buy
2024-04-29 ダウングレード Guggenheim Buy → Neutral
2024-01-24 開始されました Goldman Neutral
2023-03-22 ダウングレード Goldman Buy → Neutral
2022-12-01 開始されました Goldman Buy
2021-12-29 再開されました Jefferies Buy
2021-06-02 開始されました H.C. Wainwright Buy
2021-02-11 開始されました Guggenheim Buy
2020-12-14 開始されました Jefferies Buy
2020-11-12 繰り返されました B. Riley Securities Buy
2020-09-25 開始されました B. Riley FBR Buy
2020-08-14 開始されました Evercore ISI Outperform
2020-07-31 開始されました Piper Sandler Overweight
2020-07-28 開始されました JMP Securities Mkt Outperform
2020-02-24 再開されました ROTH Capital Buy
2019-07-19 開始されました ROTH Capital Buy
2017-10-09 開始されました Piper Jaffray Overweight
すべてを表示

Altimmune Inc (ALT) 最新ニュース

pulisher
Jun 13, 2025

Altimmune Announces Multiple Presentations at Upcoming American - GuruFocus

Jun 13, 2025
pulisher
Jun 13, 2025

Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions - The Manila Times

Jun 13, 2025
pulisher
Jun 13, 2025

Breakthrough GLP-1/Glucagon Drug Pemvidutide Reveals Multiple Cardiometabolic Benefits in New Clinical Data - Stock Titan

Jun 13, 2025
pulisher
Jun 10, 2025

Kalkine : Altimmune’s Role in NASDAQ Composite Amid Biotech Sector Momentum - Kalkine Media

Jun 10, 2025
pulisher
Jun 05, 2025

Altimmune, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 05, 2025

Two Sigma Advisers LP Sells 22,700 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Nuveen Asset Management LLC Has $1.56 Million Stock Position in Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Sells 33,984 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel analysts reaffirm Altimmune stock rating with $18 price target - Investing.com India

Jun 02, 2025
pulisher
Jun 02, 2025

Altimmune, Inc. (NASDAQ:ALT) Shares Bought by ProShare Advisors LLC - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

Altimmune, Inc. (NASDAQ:ALT) Stock Holdings Increased by Millennium Management LLC - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire

May 31, 2025
pulisher
May 29, 2025

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha

May 29, 2025
pulisher
May 29, 2025

Altimmune, Inc. (NASDAQ:ALT) Shares Bought by Deutsche Bank AG - Defense World

May 29, 2025
pulisher
May 28, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

May 28, 2025
pulisher
May 26, 2025

FY2029 EPS Estimate for Altimmune Decreased by Analyst - Defense World

May 26, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Altimmune (NASDAQ:ALT) to “Hold” - Defense World

May 24, 2025
pulisher
May 22, 2025

ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World

May 22, 2025
pulisher
May 21, 2025

Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN

May 21, 2025
pulisher
May 21, 2025

How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN

May 21, 2025
pulisher
May 21, 2025

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com

May 21, 2025
pulisher
May 20, 2025

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga

May 20, 2025
pulisher
May 19, 2025

Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Altimmune begins phase 2 trial for AUD treatment - Investing.com

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World

May 19, 2025
pulisher
May 17, 2025

William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World

May 17, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 17, 2025
pulisher
May 17, 2025

B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

(ALT) Proactive Strategies - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN

May 16, 2025
pulisher
May 16, 2025

Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter

May 16, 2025
pulisher
May 16, 2025

Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 16, 2025
pulisher
May 15, 2025

Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 15, 2025
pulisher
May 15, 2025

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN

May 15, 2025
pulisher
May 14, 2025

Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks

May 14, 2025

Altimmune Inc (ALT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Altimmune Inc (ALT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
WEAVER GREGORY L
Chief Financial Officer
Mar 13 '25
Buy
5.20
10,000
51,996
10,000
Garg Vipin K
President and CEO
Feb 02 '25
Option Exercise
0.00
18,950
0
363,364
Garg Vipin K
President and CEO
Feb 01 '25
Option Exercise
0.00
16,545
0
351,645
Garg Vipin K
President and CEO
Jan 30 '25
Option Exercise
0.00
26,775
0
342,696
Harris Matthew Scott
Chief Medical Officer
Feb 02 '25
Option Exercise
0.00
7,775
0
84,564
Harris Matthew Scott
Chief Medical Officer
Feb 01 '25
Option Exercise
0.00
6,166
0
78,898
Harris Matthew Scott
Chief Medical Officer
Jan 30 '25
Option Exercise
0.00
9,275
0
74,000
Roberts M Scot
Chief Scientific Officer
Feb 02 '25
Option Exercise
0.00
7,775
0
75,536
Roberts M Scot
Chief Scientific Officer
Feb 01 '25
Option Exercise
0.00
6,166
0
69,562
Roberts M Scot
Chief Scientific Officer
Jan 30 '25
Option Exercise
0.00
9,275
0
62,921
$20.48
price down icon 1.21%
$35.87
price down icon 0.73%
$21.02
price up icon 0.67%
$104.90
price down icon 1.02%
$102.67
price down icon 2.16%
biotechnology ONC
$266.38
price up icon 0.07%
大文字化:     |  ボリューム (24 時間):